Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA (2014) In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer
Key Takeaway: The article discusses a study involving the MET-specific Anticalin 89Zr-PRS-110 PET tracer for in vivo visualization of MET tumor expression and biodistribution. The authors include various researchers and the text provides a brief overview without detailed findings or conclusions. Further information on the study's implications or results is not provided.
Price reaction · baseline $22.05 (2025-06-20 close) · hit pre-market · clean, no other PVLA news in the window
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita